In addition to facilitating healthcare delivery planning, reliable information about prognosis is
essential for treatment decisions in patients with idiopathic pulmonary fibrosis (IPF). This …

Background There are substantial advances in diagnosis and treatment for idiopathic
pulmonary fibrosis (IPF), but without much evidence available on recent mortality and …

Background Observational data under real-life conditions in idiopathic pulmonary fibrosis
(IPF) is scarce. We explored anti-fibrotic treatment, disease severity and phenotypes in …

Objective There is a paucity of observational data on antifibrotic therapy for idiopathic
pulmonary fibrosis (IPF). We aimed to assess the course of disease of IPF patients with and …

In patients with idiopathic pulmonary fibrosis (IPF), the effects of antifibrotic agents on the
prognosis remain unclear. This study aimed to investigate the impact of antifibrotic treatment …

Background Patients with idiopathic pulmonary fibrosis (IPF) frequently have multiple
comorbidities, which may influence survival but go under-recognised in clinical practice. We …

Background Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the
European Medicines Agency and the US Food and Drug Administration for the treatment of …

Rationale: In recent decades, diagnosis and treatment recommendations for idiopathic
pulmonary fibrosis (IPF) have changed. In Korea, the average life expectancy has increased …

Background Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease associated with
high morbidity and mortality. Effective treatments for IPF are limited. Several recent studies …

Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung
disease associated with significant morbidity and mortality. Nintedanib and pirfenidone are …